2400 Journal of Medicinal Chemistry, 2010, Vol. 53, No. 6
Smits et al.
also goes out to Prof. Dr. Eric Haaksma, Dr. Ivo van
Stokkum, and Dr. Chris de Graaf for their interesting
discussions on QSAR. The histamine H4R research is sup-
ported by COST BM0806 (European Cooperation in Science
and Technology).
based design of new H4 receptor-ligands with anti-inflammatory
properties in vivo. J. Med. Chem. 2008, 51, 2457–2467.
(13) Smits, R., A.; de Esch, I. J. P.; Zuiderveld, O., P.; Broeker, J.;
Sansuk, K.; Guaita, E.; Coruzzi, G.; Adami, M.; Haaksma, E.;
Leurs, R. Discovery of quinazolines as histamine H4 receptor
inverse agonists using a scaffold hopping approach. J. Med. Chem.
2008, 51, 7855–7865.
(14) Smits, R. A.; Lim, H. D.; Stegink, B.; Bakker, R. A.; de Esch,
I. J. P.; Leurs, R. Characterization of the histamine H4 receptor
binding site: Part I. Synthesis and pharmacological evaluation of
dibenzodiazepine derivatives. J. Med. Chem. 2006, 49, 4512–4516.
(15) Winterbottom, R.; Clapp, J. W.; Miller, W. H.; English, J. P.;
Roblin, R. O. Studies in chemotherapy. XV. Amides of pantoyl-
taurine. J. Am. Chem. Soc. 1947, 69, 1393–1400.
(16) Miller, E.; Sprague, J. M.; Kissinger, L. W.; McBurney, L. F. The
preparation of some amino sulfonamides. J. Am. Chem. Soc. 1940,
62, 2099–2103.
(17) Lee, A. H. F.; Kool, E. T. Novel benzopyrimidines as widened
analogues of DNA bases. J. Org. Chem. 2005, 70, 132–140.
(18) MOE: Molecular Operating Environment, version 2006.08; Chemi-
cal Computing Group, Inc.: Montreal, Canada, 2006.
(19) Shahapurkar, S.; Pandya, T.; Kawathekar, N.; Chaturvedi, S. C.
Quantitative structure-activity relationship studies of diaryl fur-
anones as selective COX-2 inhibitors. Eur. J. Med. Chem. 2004, 39,
899–904.
Supporting Information Available: Experimental details for
compounds 3, 7b, 8, 11, 12, 13a, 13b, 14, 15, 17, 18, 33-36, 38,
39, 41-44, 46, 47-61, 82, 89-104. LCMS purity data for
compounds 3, 48-61, 82, and 98-104 as determined by LCMS.
Values and correlation matrix of the most influential descriptors
from eq 1. This material is available free of charge via the
References
(1) Oda, T.; Morikawa, N.; Saito, Y.; Masuho, Y.; Matsumoto, S.
Molecular cloning and characterization of a novel type of hista-
mine receptor preferentially expressed in leukocytes. J. Biol. Chem.
2000, 275, 36781–36786.
(2) Thurmond, R. L.; Gelfand, E. W.; Dunford, P. J. The role of
histamine H1 and H4 receptors in allergic inflammation: the search
for new antihistamines. Nat. Rev. Drug Discovery 2008, 7, 41–53.
(3) Thurmond, R. L.; Desai, P. J.; Dunford, P. J.; Fung-Leung, W. P.;
Hofstra, C. L.; Jiang, W.; Nguyen, S.; Riley, J. P.; Sun, S.;
Williams, K. N.; Edwards, J. P.; Karlsson, L. A potent and selective
histamine H4 receptor antagonist with anti-inflammatory proper-
ties. J. Pharmacol. Exp. Ther. 2004, 309, 404–413.
(4) Zhu, Y .; Michalovich, D.; Wu, H.-L.; Tan, K. B.; Dytko, G. M.;
Mannan, I. J.; Boyce, R.; Alston, J.; Tierney, L. A.; Li, X.; Herrity,
N. C.; Vawter, L.; Sarau, H. M.; Ames, R. S.; Davenport, C. M.;
Hieble, J. P.; Wilson, S.; Bergsma, D. J.; Fitzgerald, L. R. Cloning,
expression and pharmacological characterization of a novel human
histamine receptor. Mol. Pharmacol. 2001, 59, 434–444.
(5) Nakamura, T.; Itadani, H.; Hidaka, Y.; Ohta, M.; Tanaka, K.
Molecular cloning and characterization of a new human histamine
receptor, HH4R. Biochem. Biophys. Res. Commun. 2000, 279, 615–620.
(6) O’Reilly, M.; Alpert, R.; Jenkinson, S.; Gladue, R., P.; Foo, S.;
Trim, S.; Peter, B.; Trevethick, M.; Fidock, M. Identification of a
histamine H4 receptor on human eosinophils;role in eosinophil
chemotaxis. J. Recept. Signal Transduction Res. 2002, 22, 431–448.
(7) Gutzmer, R.; Diestel, C.; Mommert, S.; Kother, B.; Stark, H.;
Wittmann, M.; Werfel, T. Histamine H4 receptor stimulation
suppresses IL-12p70 production and mediates chemotaxis in
human monocyte-derived dendritic cells. J. Immunol. 2005, 174,
5224–5232.
(8) Takeshita, K.; Bacon, K., B.; Ganter, F. Critical role of L-selectin
and histamine H4 receptor in zymosan-induced neutrophil recruit-
ment from the bone marrow: comparison with carrageenan.
J. Pharmacol. Exp. Ther. 2004, 310, 272–280.
(9) Takeshita, K.; Sakai, K.; Bacon, K., B.; Ganter, F. Critical role of
histamine H4 receptor in leukotriene B4 production and mast cell-
dependent neutrophil recruitment induced by zymosan in vivo.
J. Pharmacol. Exp. Ther. 2003, 307, 1072–1078.
(10) Venable, J. D.; Cai, H.; Chai, W.; Dvorak., C. A.; Grice, C. A.;
Jablonowski, J. A.; Shah, C. R.; Kwok, A. K.; Ly, K. S.; Pio, B.;
Wei, J.; Desai, P. J; Jiang, W.; Nguyen, S.; Ling, P.; Wilson, S. J.;
Dunford, P. J.; Thurmond, R. L.; Lovenberg, T. W.; Karlsson, L.;
Carruthers, N. I.; Edwards, J. P. Preparation and biological
evaluation of indole, benzimidazole, and thienopyrrole piperazine
carboxamides: potent human histamine h(4) antagonists. J. Med.
Chem. 2005, 48, 8289–8298.
(11) Lim, H. D.; van Rijn, R. M.; Ling, P.; Bakker, R. A.; Thurmond,
R. L.; Leurs, R. Evaluation of histamine H1-, H2-, and H3-receptor
ligands at the human histamine H4 receptor: Identification of 4-
methylhistamine as the first potent and selective histamine H4
receptor agonist. J. Pharmacol. Exp. Ther. 2005, 314, 1310–1321.
(12) Smits, R., A.; Lim, H., D.; Hanzer, A.; Zuiderveld, O. P.; Guaita,
E.; Adami, M.; Coruzzi, G.; Leurs, R.; de Esch, I. J. P. Fragment
(20) Halgren, T. A. Merck molecular force field. I. Basis, form, scope,
parameterization, and performance of MMFF94. J. Comput.
Chem. 1996, 17, 490–519.
(21) Halgren, T. A. Merck molecular force field. III. Molecular geo-
metries and vibrational frequencies for MMFF94. J. Comput.
Chem. 1996, 17, 553–586.
(22) Golbraikh, A.; Tropsha, A. Beware of q2!. J. Mol. Graphics Modell.
2002, 20, 269–276.
(23) Eriksson, L.; Jaworska, J.; Worth, A. P.; Cronin, M. T.; McDowell,
R. M.; Gramatica, P. Methods for reliability and uncertainty assess-
ment and for applicability evaluations of classification- and regression-
based QSARs. Environ. Health Perspect. 2003, 111, 1361–1375.
(24) Gasteiger, J.; Marsili, M. Iterative partial equalization of orbital
electronegativity a rapid access to atomic charges. Tetrahedron
1980, 36, 3219–3228.
(25) Petitjean, M. Applications of the radius-diameter diagram to the
classification of topological and geometrical shapes of chemical
compounds. J. Chem. Inf. Comput. Sci. 1992, 32, 331–337.
(26) Wildman, S. A.; Crippen, G. M. Prediction of Physicochemical
Parameters by Atomic Contributions. J. Chem. Inf. Comput. Sci.
1999, 39, 868–873.
(27) Afantitis, A.; Melagraki, G.; Sarimveis, H.; Igglessi-Markopoulou,
O.; Kollias, G. A novel QSAR model for predicting the inhibition
of CXCR3 receptor by 4-N-aryl-[1,4] diazepane ureas. Eur. J. Med.
Chem. 2009, 44, 877–884.
(28) Todeschini, R.; Consonni, V.; Mauri, A.; Pavan, M. Detecting
“bad” regression models: multicriteria fitness functions in regres-
sion analysis. Anal. Chim. Acta 2004, 515, 199–208.
(29) Jablonowski, J. A.; Grice, C. A.; Dvorak, C. A.; Venable, J. D.;
Kwok, A. K.; Ly, K. S.; Wei, J.; Baker, S. M.; Desai, P. J.; Jiang,
W.; Wilson, S. J.; Thurmond, R. L.; Karlsson, L.; Edwards, J. P.;
Lovenberg, T. W.; Carruthers, N. I. The first potent and selective
non-imidazole human histamine H4 receptor antagonists. J. Med.
Chem. 2003, 19, 3957–3960.
(30) Terzioglu, N.; van Rijn, R. M.; Bakker, R. A.; de Esch, I. J. P.;
Leurs, R. Synthesis and structure-activity relationships of indole-
and benzimidazole piperazines as histamine H4 receptor antago-
nists. Bioorg. Med. Chem. Lett. 2004, 14, 5251–5256.
(31) Coruzzi, G.; Adami, M.; Guaita, E.; de Esch, I. J. P.; Leurs, R.
Antinflammatory and antinociceptive effects of the selective hista-
mine H4-receptor antagonists JNJ7777120 and VUF6002 in a rat
model of carrageenan-induced inflammation. Eur. J. Pharmacol.
2007, 563, 240–244.
(32) Andersen, L.; Sundman, L.-O.; Linden, I.-B.; Kontro, K.; Oja, S. S.
Synthesis and anticonvulsant properties of some 2-aminoethane-
sulfonic acid (taurine) derivatives. J. Pharm. Sci. 1984, 73, 106–108.